5243722025-07-012025-09-305243722025-09-305243722025-03-315243722025-04-012025-09-305243722025-07-012025-09-30in-capmkt:OtherExpenses1Member5243722025-04-012025-09-30in-capmkt:OtherExpenses1Member5243722025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027Orchid Pharma LimitedMain BoardEquity2025-04-012026-03-312025-11-112025-11-05INRLakhsQuarterlySecond quarterSingle segmentPharmaceutical2025-11-1112:00:002025-11-1115:00:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated193524200010774400020429860001122677000173400020065400024850600037323000890140003764270002076335000-333490000-333490000000-33349000000-23887000-57236000-3945000-6118100050719100010-1.13-1.1300-1.13-1.131. The above results for the quarter and half year ended September 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on November 11, 2025. The statutory auditors of the company have expressed a modified conclusion on the Limited review. <BR> 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <BR> 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. <BR> As on September 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <BR> Statement of QIP Net Funds raised and utilisation <BR> Particulars Amount as stated in Total amount utilised Balance amount as on Remarks <BR> the Offer Document upto September 30, 2025 on September 30, 2025 kept <BR> Rs. In Lakhs, revised In Lakhs in Fixed Deposits Rs.in lakhs <BR> 1. Investment in OBPL, <BR> subsidiary, for setting up <BR> Jammu Manufacturing Facility 13500 7302 6198 <BR> 2. Repayment/prepayment, in <BR> full or in part, of certain <BR> outstanding borrowings <BR> availed by the company 19546 14100 5446 <BR> 3. Funding capital expenditure <BR> requirements for setting up a <BR> new block at the API facility <BR> of the Company in Alathur, <BR> Tamil Nadu 36 36 0 <BR> 4. General corporate purposes 6098 6372 0 <BR> Total 39180 27810 11644 <BR> <BR> As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on September 30, 2025. The allocation among the objects has been revised vide Shareholder Resolution dated September 20, 2025. <BR> Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. <BR> <BR> 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. <BR> 5. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the <BR> Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, <BR> in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, <BR> giving No objection to the said amalgamation. <BR> The requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, During its hearing held on September 24, 2025, Honble NCLT issued directions to the Office of OffiCial Liquidator and Regional Director to submit their report in the next hearing on November 26, 2025. he Report of Income tax department has already been filed. <BR> <BR> 6. The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH. Germany and Allecra Therapeutics SAS. France on October 29, 2025 and August 01, 2025 respectively. After the successful completion of above transactions. Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam, International Brand Name known as EXBLIFEP, known as Orblicef in India, consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India back to India. <BR> <BR> 7. The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH. a Company incorporated under laws of Germany. now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. <BR> July 30, 2025. <BR> 8. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.2025-04-012025-09-30UnauditedConsolidated36645300002222200003886750000222425100096130007985500046463500069898000175555000759180000378298700010376300001037630000-1483000-14830000105246000000-1189300093353000-549300087860000507191000101.841.84001.841.84Other Expenses376427000Other Expenses759180000615056900012031760000073310001483170000048508100000427530005278340004871170001649367000101737110003062205000020217270004198720001065161000010731000351749100019894000444691000704428100002495000172204870005071910001223124200012738433000127384330002340348000000023403480003995900000023803070004720370009858500013908370001489422000019614590001185030002178500000210174700000448205400017220487000698980002015100004785730000929440000000-7321270000001755550000-684950000-550000-108911000051660000000-83911000527900000-2140000082363000000-32733000011509600000000000015875110008966200000000000000000000713650000520096000-906388000000000001012704000000126080000010000960002088040000208804000211068000419872000Items that will not be reclassified to profit and loss-3945000-3945000Items that will not be reclassified to profit and loss-5493000-54930000000-3945000-5493000